• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

恶性胸膜间皮瘤行胸膜切除术/剥脱术后改行胸膜外全肺切除术的结果。

Outcomes of Conversion to Extrapleural Pneumonectomy From Pleurectomy/Decortication for Malignant Pleural Mesothelioma.

机构信息

Divisions of Thoracic Surgery and Respiratory Medicine, Department of Surgery, Hyogo College of Medicine, Hyogo, Japan.

Divisions of Thoracic Surgery and Respiratory Medicine, Department of Surgery, Hyogo College of Medicine, Hyogo, Japan.

出版信息

Semin Thorac Cardiovasc Surg. 2021 Autumn;33(3):873-881. doi: 10.1053/j.semtcvs.2021.02.003. Epub 2021 Feb 18.

DOI:10.1053/j.semtcvs.2021.02.003
PMID:33609685
Abstract

In recent years, there has been a shift from extrapleural pneumonectomy (EPP) toward pleurectomy/decortication (P/D) as the preferred surgical technique. However, we occasionally encounter difficult cases wherein visceral pleurectomy requires conversion to EPP from P/D. We sought to clarify the preoperative risk factors and clinical outcomes associated with conversion to EPP. We compared and analyzed conversion to EPP and P/D between September 2012 and December 2019. Conversion to EPP was decided in case of diffuse tumor invasion to the pulmonary parenchyma or due to failure of decortication. Univariable regression analysis was performed to determine the association of preoperative variables with conversion to EPP. Survival was analyzed by the Kaplan-Meier method and log-rank test. Of the 181 patients who underwent intended P/D, 145 (80.1%) patients underwent P/D and 18 (9.9%) patients underwent conversion to EPP. The sum of 3-level pleural thickness (P < 0.001), maximum of 3-level pleural thickness (P = 0.006), and clinical T stage (P < 0.001) demonstrated association with conversion to EPP. Overall survival and progression-free survival were significantly worse in the conversion to EPP group (median overall survival, 29.2 months vs 57.0 months [P = 0.008]; median progression-free survival, 15.3 months vs 23.2 months [P = 0.005]. Our data show that approximately 1 of every 10 patients with P/D intention converted to EPP. Preoperative pleural thickness and clinical T stage may be risk factors associated with conversion to EPP. The survival rate of conversion to EPP was worse than that of P/D.

摘要

近年来,人们已从施行胸膜外全肺切除术(EPP)转向施行胸膜切除术/剥除术(P/D),将其作为首选的手术技术。然而,我们偶尔会遇到困难的病例,这些病例中的内脏胸膜切除术需要从 P/D 转为 EPP。我们旨在阐明与转为 EPP 相关的术前风险因素和临床结局。我们比较和分析了 2012 年 9 月至 2019 年 12 月期间转为 EPP 和 P/D 的病例。如果肿瘤广泛侵犯肺实质或剥除术失败,则决定转为 EPP。使用单变量回归分析来确定与转为 EPP 相关的术前变量的关联。使用 Kaplan-Meier 方法和对数秩检验分析生存情况。在 181 例行计划 P/D 的患者中,145 例(80.1%)患者接受了 P/D,18 例(9.9%)患者转为 EPP。3 级胸膜厚度总和(P<0.001)、3 级胸膜最大厚度(P=0.006)和临床 T 分期(P<0.001)与转为 EPP 相关。转为 EPP 组的总生存和无进展生存明显较差(中位总生存,29.2 个月比 57.0 个月[P=0.008];中位无进展生存,15.3 个月比 23.2 个月[P=0.005])。我们的数据显示,约每 10 例计划行 P/D 的患者中就有 1 例转为 EPP。术前胸膜厚度和临床 T 分期可能是与转为 EPP 相关的风险因素。转为 EPP 的生存率比 P/D 差。

相似文献

1
Outcomes of Conversion to Extrapleural Pneumonectomy From Pleurectomy/Decortication for Malignant Pleural Mesothelioma.恶性胸膜间皮瘤行胸膜切除术/剥脱术后改行胸膜外全肺切除术的结果。
Semin Thorac Cardiovasc Surg. 2021 Autumn;33(3):873-881. doi: 10.1053/j.semtcvs.2021.02.003. Epub 2021 Feb 18.
2
Is Pleurectomy/Decortication Superior to Extrapleural Pneumonectomy for Patients with Malignant Pleural Mesothelioma? A Single-Institutional Experience.对于恶性胸膜间皮瘤患者,胸膜切除术/纤维板剥脱术是否优于胸膜外全肺切除术?一项单机构经验。
Ann Thorac Cardiovasc Surg. 2018 Apr 20;24(2):81-88. doi: 10.5761/atcs.oa.17-00192. Epub 2018 Jan 23.
3
Surgical strategy for malignant pleural mesothelioma: the superiority of pleurectomy/decortication.恶性胸膜间皮瘤的外科治疗策略:胸膜切除术/剥脱术的优势。
Surg Today. 2022 Jul;52(7):1031-1038. doi: 10.1007/s00595-021-02437-9. Epub 2022 Jan 19.
4
Extrapleural Pneumonectomy Versus Pleurectomy/Decortication for Malignant Pleural Mesothelioma.胸膜外全肺切除术与胸膜剥脱/肺切除术治疗恶性胸膜间皮瘤。
Ann Thorac Surg. 2022 Jan;113(1):200-208. doi: 10.1016/j.athoracsur.2021.04.078. Epub 2021 May 8.
5
Current Treatment of Mesothelioma: Extrapleural Pneumonectomy Versus Pleurectomy/Decortication.间皮瘤的当前治疗方法:胸膜外全肺切除术与胸膜剥脱术/去皮质术对比
Thorac Surg Clin. 2016 Aug;26(3):359-75. doi: 10.1016/j.thorsurg.2016.04.003.
6
Extrapleural pneumonectomy versus pleurectomy/decortication in the surgical management of malignant pleural mesothelioma: results in 663 patients.胸膜外肺切除术与胸膜剥脱术/纤维板剥脱术治疗恶性胸膜间皮瘤的手术疗效:663例患者的结果
J Thorac Cardiovasc Surg. 2008 Mar;135(3):620-6, 626.e1-3. doi: 10.1016/j.jtcvs.2007.10.054. Epub 2008 Feb 14.
7
Radical pleurectomy and chemoradiation for malignant pleural mesothelioma: the outcome of incomplete resections.根治性胸膜切除术和放化疗治疗恶性胸膜间皮瘤:不完全切除的结果。
Lung Cancer. 2013 Aug;81(2):241-6. doi: 10.1016/j.lungcan.2013.04.019. Epub 2013 May 17.
8
Propensity matched comparison of extrapleural pneumonectomy and pleurectomy/decortication for mesothelioma patients.胸膜外肺切除术与胸膜剥脱术/纤维板剥脱术治疗间皮瘤患者的倾向评分匹配比较
Interact Cardiovasc Thorac Surg. 2017 May 1;24(5):740-746. doi: 10.1093/icvts/ivw422.
9
Malignant pleural mesothelioma and the Society of Thoracic Surgeons Database: an analysis of surgical morbidity and mortality.恶性胸膜间皮瘤和胸外科医生协会数据库:手术发病率和死亡率分析。
J Thorac Cardiovasc Surg. 2014 Jul;148(1):30-5. doi: 10.1016/j.jtcvs.2014.03.011. Epub 2014 Mar 14.
10
Systematic review of quality of life following pleurectomy decortication and extrapleural pneumonectomy for malignant pleural mesothelioma.系统评价行胸膜剥脱肺切除术和胸膜外全肺切除术治疗恶性胸膜间皮瘤的生活质量。
BMC Cancer. 2018 Nov 29;18(1):1188. doi: 10.1186/s12885-018-5064-4.

引用本文的文献

1
Peritoneal Dissemination in Patients with Recurrence After Post-pleurectomy/decortication for Pleural Mesothelioma.胸膜间皮瘤行胸膜切除/剥脱术后复发患者的腹膜播散。
Ann Surg Oncol. 2024 Nov;31(12):7767-7774. doi: 10.1245/s10434-024-15984-5. Epub 2024 Aug 10.
2
Nationwide prospective registry database of patients with newly diagnosed untreated pleural mesothelioma in Japan.日本新诊断未经治疗的胸膜间皮瘤患者的全国前瞻性登记数据库。
Cancer Sci. 2024 Feb;115(2):507-528. doi: 10.1111/cas.16021. Epub 2023 Dec 4.
3
Do we still need to debate the merits of pleurectomy/decortication extrapleural pneumonectomy for malignant pleural mesothelioma?
对于恶性胸膜间皮瘤,我们是否仍需对胸膜切除术/胸膜剥脱术与胸膜外全肺切除术的优缺点展开辩论?
Transl Lung Cancer Res. 2023 Feb 28;12(2):193-196. doi: 10.21037/tlcr-23-24. Epub 2023 Feb 6.
4
Efficacy and safety of nivolumab with ipilimumab for recurrent malignant pleural mesothelioma after primary surgical intervention.纳武利尤单抗联合伊匹单抗治疗初治手术干预后复发恶性胸膜间皮瘤的疗效和安全性。
Int J Clin Oncol. 2023 Mar;28(3):409-415. doi: 10.1007/s10147-023-02292-3. Epub 2023 Jan 7.
5
New Era for Malignant Pleural Mesothelioma: Updates on Therapeutic Options.恶性胸膜间皮瘤的新纪元:治疗选择的最新进展。
J Clin Oncol. 2022 Feb 20;40(6):681-692. doi: 10.1200/JCO.21.01567. Epub 2022 Jan 5.